Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

By G. von Minckwitz, A. Schneeweiss, S. Loibl, C. Salat, Carsten Denkert, M. Rezai, J. Blohmer, C. Jackisch, S. Paepke, B. Gerber and 16 more. The Lancet Oncology, 2014

906 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/3a6178a2382086488fee829927c62118273080f3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Lisa A. Carey

In Oncology

1. Yongheng Chen
2. S. Leonov
3. Huajun Zhang
4. Lin Chen
5. Na Liu
6. Yun R Li
7. Yulia Merkher

Citations in the corpus

• Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline (2021, methodology): “005).(13) Treatment discontinuation wasmore frequent in patients who received carboplatin than in those who did not receive carboplatin (48% v 39%).”
• Triple-negative breast cancer molecular subtyping and treatment progress (2020, background): “that increase was not observed in patients with HER2positive breast cancer [38].”
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, background): “Neoadjuvant systemic therapies An improved pCR rate was observed with carboplatin for patients with triple-negative disease [75, 76].”
• Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer (2016, neutral): “[0,5] (10,15] (20,25] (30,35] (40,45] (50,55] (60,65] (70,75] (80,85] (90,95] BRCA Intact (n = 790) BRCA Deficient (n = 268)”